gabexate has been researched along with Fibrous Dysplasia of Bone in 1 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
Fibrous Dysplasia of Bone: A disease of bone marked by thinning of the cortex by fibrous tissue containing bony spicules, producing pain, disability, and gradually increasing deformity. Only one bone may be involved (FIBROUS DYSPLASIA, MONOSTOTIC) or several (FIBROUS DYSPLASIA, POLYOSTOTIC).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saito, A | 1 |
| Tsukawaki, Y | 1 |
| Nioka, S | 1 |
| Yoda, K | 1 |
| Miyazaki, M | 1 |
| Kusaka, Y | 1 |
| Ban, S | 1 |
1 other study available for gabexate and Fibrous Dysplasia of Bone
| Article | Year |
|---|---|
[Pre- and post-operative management of Kasabach-Merritt syndrome].
Topics: Blood Coagulation; Disseminated Intravascular Coagulation; Fibrous Dysplasia of Bone; Fibrous Dyspla | 1984 |